2020
DOI: 10.1128/cmr.00043-19
|View full text |Cite
|
Sign up to set email alerts
|

Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation

Abstract: SUMMARY Hosts with compromised or naive immune systems, such as individuals living with HIV/AIDS, transplant recipients, and fetuses, are at the highest risk for complications from cytomegalovirus (CMV) infection. Despite substantial progress in prevention, diagnostics, and treatment, CMV continues to negatively impact both solid-organ transplant (SOT) and hematologic cell transplant (HCT) recipients. In this article, we summarize important developments in the field over the past 10 years and highlight new app… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
70
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 67 publications
(71 citation statements)
references
References 273 publications
(356 reference statements)
0
70
0
1
Order By: Relevance
“…CMV is currently a major health problem, in particular for patients with impaired cell-mediated immunity [2], such as solid organ transplant recipients, hematopoietic cell transplant recipients [3], HIVinfected patients [4], and patients treated with immunomodulating drugs [5]. For those immunocompromised patients, CMV infection or reactivation cause several morbidities, including gastrointestinal tract disease, pneumonia, hepatitis, and encephalitis, as well as increasing the chance of organ rejection and opportunistic infections [6]. Hence, CMV viral load monitoring is recommended.…”
Section: Introductionmentioning
confidence: 99%
“…CMV is currently a major health problem, in particular for patients with impaired cell-mediated immunity [2], such as solid organ transplant recipients, hematopoietic cell transplant recipients [3], HIVinfected patients [4], and patients treated with immunomodulating drugs [5]. For those immunocompromised patients, CMV infection or reactivation cause several morbidities, including gastrointestinal tract disease, pneumonia, hepatitis, and encephalitis, as well as increasing the chance of organ rejection and opportunistic infections [6]. Hence, CMV viral load monitoring is recommended.…”
Section: Introductionmentioning
confidence: 99%
“…A few antiviral drugs, including ganciclovir and valganciclovir, have been used for treating CMV infection, but viral resistance is a major challenge associated with their use [ 1 ]. Another approach is the transfer of donor-derived CMV-specific CTLs, but it remains limited due to the occurrence of graft-versus-host disease (GVHD) in allogeneic recipients [ 25 ].…”
Section: Discussionmentioning
confidence: 99%
“…Human cytomegalovirus (CMV), a β-herpes virus with a double-stranded DNA, infects a wide variety of cells and establishes latency in the host [ 1 ]. CMV infection is very common in adults (60‒90% of the population), with higher infection rates with age [ 2 ], and is usually asymptomatic in healthy subjects but can cause severe diseases in immunocompromised patients with cellular immunosuppression or immunodeficiency, including transplant recipients and fetuses [ 1 , 3 ].…”
Section: Introductionmentioning
confidence: 99%
“…Cytomegalovirus is a severe virus which causes deadly infections among immunosuppressed patients [42]. Human cytomegalovirus (HCMV) open reading frames (ORF) encodes four vGPCRs: US28, US27, UL33, and UL78; the first three mimic chemokine receptor structure.…”
Section: Cytomegalovirus (Cmv)mentioning
confidence: 99%